^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + bortezomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Based on with the above results, bortezomib/lenalidomide/dexamethasone, the NCCN Panel included this regimen as a category 1, preferred option for primary treatment of transplant-eligible patients with MM.
Multiple Myeloma: Maintenance therapy…Useful In Certain Circumstances…Bortezomib/lenalidomide +/- dexamethasone
Secondary therapy:
dexamethasone
